Early results of a phase I evaluation of TAK-228 (TORC 1/2 inhibitor) in combination with TAK-117 (PI3K alpha inhibitor) and paclitaxel in advanced gynecologic malignancies and metastatic breast cancer
Casey Williams(Creighton University), David Starks(Cleveland Clinic), Luis Rojas‐Espaillat(Avera McKennan Hospital & University Health Center), Amy Krie(Amgen (United States)), Kirstin Williams(Avera Health), Robert W. Coppock, S. Schwingler(Avera Health), Brian Leyland‐Jones(Avera Health), Natasha Flier(Avera Health), G. Middendorff(Avera Health), Nandini Dey(University of South Dakota), Pradip De(University of South Dakota), Robin Lockhorst(Avera Health)
Cited by 0
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
|Nature Medicine|2019|726
Laparoendoscopic single-site surgery (LESS) in gynecology: a multi-institutional evaluation
|American Journal of Obstetrics and Gynecology|2010|136
RET rearrangements are actionable alterations in breast cancer
|Nature Communications|2018|127